Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gavin P Reynolds

Showing results (11-20 of 136) with videos related to

Pageof 14
Sort By:
Journal of Psychopharmacology (Oxford, England)|August 20, 2025
The pharmacology underlying the unique antipsychotic efficacy of clozapineGavin P Reynolds
Journal of Psychopharmacology (Oxford, England)|April 3, 2026
Antipsychotic action and symptom specificity - down the bioinformatic rabbit holeGavin P Reynolds
The International Journal of Neuropsychopharmacology|July 2, 2024
Understanding the Therapeutic Action of Antipsychotics: Not yet Beyond Striatal Dopamine? A Comment on Direktor et al. (2024)Gavin P Reynolds
The International Journal of Neuropsychopharmacology|July 12, 2021
The Etiology of Metabolic Disturbances in Schizophrenia: Drugs, Genes, and EnvironmentGavin P Reynolds
Drug Discovery Today|November 13, 2007
The impact of pharmacogenetics on the development and use of antipsychotic drugsGavin P Reynolds
Psychiatry Investigation|March 8, 2012
The pharmacogenetics of symptom response to antipsychotic drugsGavin P Reynolds
Journal of Psychopharmacology (Oxford, England)|July 28, 2007
Schizophrenia, antipsychotics and metabolic diseaseGavin P Reynolds
Journal of Psychopharmacology (Oxford, England)|November 30, 2012
Histamine and antipsychotic drug-induced weight gainGavin P Reynolds
Journal of Neural Transmission (Vienna, Austria : 1996)|December 22, 2021
The neurochemical pathology of schizophrenia: post-mortem studies from dopamine to parvalbuminGavin P Reynolds
Diabetes|May 5, 2023
Comment on Tabatabaei Dakhili et al. The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase. Diabetes 2023;72:126-134Gavin P Reynolds
Pageof 14

Showing results (11-20 of 136) with videos related to

Sort By:
Pageof 14
Journal of Psychopharmacology (Oxford, England)|August 20, 2025
The pharmacology underlying the unique antipsychotic efficacy of clozapineGavin P Reynolds
Journal of Psychopharmacology (Oxford, England)|April 3, 2026
Antipsychotic action and symptom specificity - down the bioinformatic rabbit holeGavin P Reynolds
The International Journal of Neuropsychopharmacology|July 2, 2024
Understanding the Therapeutic Action of Antipsychotics: Not yet Beyond Striatal Dopamine? A Comment on Direktor et al. (2024)Gavin P Reynolds
The International Journal of Neuropsychopharmacology|July 12, 2021
The Etiology of Metabolic Disturbances in Schizophrenia: Drugs, Genes, and EnvironmentGavin P Reynolds
Drug Discovery Today|November 13, 2007
The impact of pharmacogenetics on the development and use of antipsychotic drugsGavin P Reynolds
Psychiatry Investigation|March 8, 2012
The pharmacogenetics of symptom response to antipsychotic drugsGavin P Reynolds
Journal of Psychopharmacology (Oxford, England)|July 28, 2007
Schizophrenia, antipsychotics and metabolic diseaseGavin P Reynolds
Journal of Psychopharmacology (Oxford, England)|November 30, 2012
Histamine and antipsychotic drug-induced weight gainGavin P Reynolds
Journal of Neural Transmission (Vienna, Austria : 1996)|December 22, 2021
The neurochemical pathology of schizophrenia: post-mortem studies from dopamine to parvalbuminGavin P Reynolds
Diabetes|May 5, 2023
Comment on Tabatabaei Dakhili et al. The Antipsychotic Dopamine 2 Receptor Antagonist Diphenylbutylpiperidines Improve Glycemia in Experimental Obesity by Inhibiting Succinyl-CoA:3-Ketoacid CoA Transferase. Diabetes 2023;72:126-134Gavin P Reynolds
Pageof 14